bromocriptine mesylate- Bromocriptine Mesylate tablet United States - English - NLM (National Library of Medicine)

bromocriptine mesylate- bromocriptine mesylate tablet

lek pharmaceuticals - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - tablet - 2.5 mg - bromocriptine mesylate tablets are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. bromocriptine mesylate treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine mesylate therapy may be used to reduce the tumor mass prior to surgery. acromegaly bromocriptine mesylate tablets are indicated in the treatment of acromegaly. bromocriptine mesylate therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately one-half of patients treated, although not usually to normal levels. since the effects of external pituitary radiation may not become maximal for

BROMOCRIPTINE MESYLATE tablet
BROMOCRIPTINE MESYLATE capsule United States - English - NLM (National Library of Medicine)

bromocriptine mesylate tablet bromocriptine mesylate capsule

sun pharmaceutical industries, inc. - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg - bromocriptine mesylate is indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. bromocriptine treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine therapy may be used to reduce the tumor mass prior to surgery. bromocriptine therapy is indicated in the treatment of acromegaly. bromocriptine therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately half of patients treated, although not usually to normal levels. since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine offers p

BROMOCRIPTINE MESYLATE tablet United States - English - NLM (National Library of Medicine)

bromocriptine mesylate tablet

american health packaging - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg - bromocriptine mesylate tablets, usp are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. bromocriptine mesylate tablets, usp treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine mesylate tablets, usp therapy may be used to reduce the tumor mass prior to surgery. bromocriptine mesylate tablets, usp are indicated in the treatment of acromegaly. bromocriptine mesylate tablets, usp therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately one-half of patien

BROMOCRIPTINE MESYLATE capsule United States - English - NLM (National Library of Medicine)

bromocriptine mesylate capsule

mylan pharmaceuticals inc. - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg - bromocriptine mesylate tablets and capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . bromocriptine treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine therapy may be used to reduce the tumor mass prior to surgery. bromocriptine mesylate tablet and capsule therapy is indicated in the treatment of acromegaly. bromocriptine therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. since the effects of external pituitary radiation may not become maximal for several years,

BROMOCRIPTINE MESYLATE tablet United States - English - NLM (National Library of Medicine)

bromocriptine mesylate tablet

padagis us llc - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg - bromocriptine mesylate tablets are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . bromocriptine mesylate tablets treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine mesylate tablets therapy may be used to reduce the tumor mass prior to surgery. bromocriptine mesylate tablets therapy is indicated in the treatment of acromegaly. bromocriptine mesylate tablets therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. since the effects of external pituitary radiation may not become

BROMOCRIPTINE MESYLATE tablet United States - English - NLM (National Library of Medicine)

bromocriptine mesylate tablet

physicians total care, inc. - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg - bromocriptine mesylate tablets and capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . bromocriptine treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine therapy may be used to reduce the tumor mass prior to surgery. bromocriptine mesylate tablet and capsule therapy is indicated in the treatment of acromegaly. bromocriptine therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately half of patients treated, although not usually to normal levels. since the effects of external pituitary radiation may not become maximal for several yea

BROMOCRIPTINE MESYLATE tablet United States - English - NLM (National Library of Medicine)

bromocriptine mesylate tablet

sandoz inc - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg - bromocriptine mesylate tablets, usp are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. bromocriptine mesylate tablets, usp treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine mesylate tablets, usp therapy may be used to reduce the tumor mass prior to surgery. bromocriptine mesylate tablets, usp are indicated in the treatment of acromegaly. bromocriptine mesylate tablets, usp therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately one-half of patients treated, although not usually to normal levels. since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine mesylate tablets, usp offers potential benefit before the effects of irradiation are manifested. bromocriptine mesylate tablets, usp are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic parkinson's disease. as adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate tablets, usp therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing "end of dose failure" on levodopa therapy. bromocriptine mesylate tablets, usp therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function ("on-off" phenomenon). continued efficacy of bromocriptine mesylate tablets, usp therapy during treatment of more than two years has not been established. data are insufficient to evaluate potential benefit from treating newly diagnosed parkinson's disease with bromocriptine mesylate tablets, usp. studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in bromocriptine mesylate tablets, usp-treated patients than in levodopa/carbidopa-treated patients. patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets, usp therapy. hypersensitivity to bromocriptine or to any of the excipients of bromocriptine mesylate, uncontrolled hypertension and sensitivity to any ergot alkaloids. in patients being treated for hyperprolactinemia, bromocriptine mesylate should be withdrawn when pregnancy is diagnosed ( see precautions, hyperprolactinemic states ). in the event that bromocriptine mesylate is reinstituted to control a rapidly expanding macroadenoma (see precautions, hyperprolactinemic states ) and a patient experiences a hypertensive disorder of pregnancy, the benefit of continuing bromocriptine mesylate must be weighed against the possible risk of its use during a hypertensive disorder of pregnancy. when bromocriptine mesylate is being used to treat acromegaly, prolactinoma, or parkinson’s disease in patients who subsequently become pregnant, a decision should be made as to whether the therapy continues to be medically necessary or can be withdrawn. if it is continued, the drug should be withdrawn in those who may experience hypertensive disorders of pregnancy (including eclampsia, preeclampsia, or pregnancy-induced hypertension) unless withdrawal of bromocriptine mesylate is considered to be medically contraindicated. the drug should not be used during the postpartum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically contraindicated. if the drug is used in the postpartum period, the patient should be observed with caution.

BROMOCRIPTINE MESYLATE capsule United States - English - NLM (National Library of Medicine)

bromocriptine mesylate capsule

zydus lifesciences limited - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 5 mg - bromocriptine mesylate tablets and capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. bromocriptine treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine mesylate tablets and/or capsules therapy may be used to reduce the tumor mass prior to surgery. bromocriptine mesylate tablets and capsules therapy is indicated in the treatment of acromegaly. bromocriptine therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. since the effects of external pituitary radiation may no

BROMOCRIPTINE MESYLATE capsule United States - English - NLM (National Library of Medicine)

bromocriptine mesylate capsule

zydus pharmaceuticals usa inc. - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 5 mg - hyperprolactinemia-associated dysfunctions bromocriptine mesylate capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. bromocriptine treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine mesylate capsule therapy may be used to reduce the tumor mass prior to surgery. acromegaly bromocriptine mesylate capsule therapy is indicated in the treatment of acromegaly. bromocriptine mesylate capsule therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. since the effects of exter

BROMOCRIPTINE MESYLATE tablet United States - English - NLM (National Library of Medicine)

bromocriptine mesylate tablet

carilion materials management - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg - bromocriptine mesylate tablets are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . bromocriptine mesylate tablets treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine mesylate tablets therapy may be used to reduce the tumor mass prior to surgery. bromocriptine mesylate tablets therapy is indicated in the treatment of acromegaly. bromocriptine mesylate tablets therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. since the effects of external pituitary radiation may not become